

# Andrés José María Ferreri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2206165/publications.pdf>

Version: 2024-02-01

258  
papers

18,595  
citations

12597

71  
h-index

17891

125  
g-index

262  
all docs

262  
docs citations

262  
times ranked

13399  
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
2	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. <i>Blood</i> , 2022, 139, 2499-2511.	0.6	42
3	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	3.2	22
4	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. <i>Advances in Hematology</i> , 2022, 2022, 1-10.	0.6	1
5	Using immunogenetics to inform immunotherapy of lymphoid malignancies. <i>Lancet Haematology</i> , the, 2022, 9, e88-e89.	2.2	0
6	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	2.8	7
7	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	3.3	47
8	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. <i>Blood Advances</i> , 2022, 6, 5811-5820.	2.5	2
9	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	0.8	8
10	Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor- $\alpha$ . <i>Pharmaceutics</i> , 2022, 14, 1414.	2.0	4
11	A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the CARMEN-phase II trial. <i>British Journal of Haematology</i> , 2021, 192, 119-128.	1.2	7
12	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	1.5	20
13	MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2021, 8, e110-e121.	2.2	54
14	MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. <i>British Journal of Haematology</i> , 2021, 193, 497-505.	1.2	41
15	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	0.6	68
16	Breaching the Blood-Brain Tumor Barrier for Tumor Therapy. <i>Cancers</i> , 2021, 13, 2391.	1.7	19
17	A phase I/II study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. <i>Blood Advances</i> , 2021, 5, 4073-4082.	2.5	9
18	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1928365.	2.1	6

#	ARTICLE	IF	CITATIONS
19	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021, 5, 640-648.	2.5	22
20	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 749-760.	1.5	1
21	Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103496.	2.0	4
22	CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL). <i>Frontiers in Oncology</i> , 2021, 11, 730194.	1.3	0
23	A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma. <i>Expert Review of Hematology</i> , 2021, , 1-11.	1.0	2
24	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	2.5	22
25	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. <i>Blood Advances</i> , 2020, 4, 1013-1019.	2.5	11
26	NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. <i>Molecular Pharmaceutics</i> , 2020, 17, 3813-3824.	2.3	6
27	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. <i>Blood Advances</i> , 2020, 4, 3648-3658.	2.5	24
28	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	6.9	27
29	Prevention of CNS relapse in diffuse large B-cell lymphoma: common sense prevails where science fails. <i>British Journal of Haematology</i> , 2020, 190, 645-647.	1.2	0
30	Patience and commitment needed to fight very rare tumours. <i>Lancet Oncology</i> , The, 2020, 21, 483-484.	5.1	0
31	Early serum <sc>TARC</sc> reduction predicts prognosis in advanced-stage <sc>Hodgkin</sc> lymphoma patients treated with a <sc>PET</sc>-adapted strategy. <i>Hematological Oncology</i> , 2020, 38, 501-508.	0.8	8
32	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020, 38, 257-265.	0.8	7
33	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020, 189, 879-887.	1.2	41
34	Rituximab in primary central nervous system lymphoma – A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	0.8	54
35	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
36	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- $\beta$ in primary CNS lymphoma. <i>Blood</i> , 2019, 134, 252-262.	0.6	43

#	ARTICLE	IF	CITATIONS
37	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	0.6	45
38	Evolving Treatments for Primary Central Nervous System Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 454-466.	1.8	35
39	Targeted therapies make room, anti-CD79b agents are coming. <i>Lancet Oncology</i> , The, 2019, 20, 898-900.	5.1	4
40	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	1.6	106
41	MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA. <i>Retina</i> , 2019, 39, 679-684.	1.0	50
42	Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. <i>Neuro-Oncology</i> , 2019, 21, 296-305.	0.6	114
43	Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning. <i>Blood</i> , 2019, 134, 2891-2891.	0.6	1
44	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
45	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
46	Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 379-393.	1.4	6
47	Clarithromycin as a repurposing drug against MALT lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 913-915.	1.2	23
48	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-462.	0.8	169
49	Seeking solutions to old problems in elderly patients with lymphoma. <i>Lancet Haematology</i> , the, 2018, 5, e235-e236.	2.2	0
50	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	2.3	64
51	mTOR Inhibitors, with Special Focus on Temozolomide and Similar Agents. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 85-105.	0.1	0
52	mTOR inhibitors and their potential role in haematological malignancies. <i>British Journal of Haematology</i> , 2017, 177, 684-702.	1.2	53
53	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , the, 2017, 4, e137-e146.	2.2	28
54	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18 FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017, 178, 588-591.	1.2	20

#	ARTICLE	IF	CITATIONS
55	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	1.9	39
56	Primary central nervous system lymphoma. Critical Reviews in Oncology/Hematology, 2017, 113, 97-110.	2.0	79
57	Bacteria associated with marginal zone lymphomas. Best Practice and Research in Clinical Haematology, 2017, 30, 32-40.	0.7	27
58	Ocular adnexal marginal zone lymphoma: Clinical presentation, pathogenesis, diagnosis, prognosis, and treatment. Best Practice and Research in Clinical Haematology, 2017, 30, 118-130.	0.7	44
59	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology, the, 2017, 4, e510-e523.	2.2	258
60	Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology American Society of Hematology Education Program, 2017, 2017, 565-577.	0.9	51
61	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of Clinical Oncology, 2017, 35, 1905-1912.	0.8	143
62	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	0.8	93
63	Chronic lymphocytic leukaemia. Critical Reviews in Oncology/Hematology, 2016, 104, 169-182.	2.0	126
64	Reply to A. Korfel et al. Journal of Clinical Oncology, 2016, 34, 1830-1831.	0.8	1
65	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 2016, 128, 3083-3100.	0.6	59
66	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). BMC Cancer, 2016, 16, 282.	1.1	53
67	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology, the, 2016, 3, e217-e227.	2.2	442
68	The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood, 2016, 127, 1642-1649.	0.6	85
69	The role of whole brain radiation in primary CNS lymphoma. Blood, 2016, 128, 32-36.	0.6	35
70	Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Ca-A Cancer Journal for Clinicians, 2016, 66, 152-171.	157.7	177
71	How we diagnose and treat vitreoretinal lymphoma. British Journal of Haematology, 2016, 173, 680-692.	1.2	113
72	Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10. Blood, 2016, 128, 1099-1099.	0.6	7

#	ARTICLE	IF	CITATIONS
73	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	1.4	19
74	RelA NF- $\kappa$ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	1.4	29
75	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	0.8	61
76	Primary central nervous system lymphoma: three linked questions in the situation puzzle of radiotherapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 1185-1187.	0.6	1
77	Gamma $\delta$ T-cell lymphomas. <i>European Journal of Haematology</i> , 2015, 94, 206-218.	1.1	69
78	Primary and secondary bone lymphomas. <i>Cancer Treatment Reviews</i> , 2015, 41, 235-246.	3.4	101
79	Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature. <i>Oncologist</i> , 2015, 20, 915-925.	1.9	31
80	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , The, 2015, 16, e322-e332.	5.1	340
81	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	2.9	48
82	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	2.9	21
83	Who Is Who in Primary Vitreoretinal Lymphoma?. <i>JAMA Oncology</i> , 2015, 1, 977.	3.4	4
84	Evaluation of NF- $\kappa$ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	2.9	17
85	High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3903-3910.	0.8	99
86	Present and future treatment options for primary CNS lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2569-2579.	0.9	16
87	Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2015, 168, 654-662.	1.2	90
88	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	0.8	72
89	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	0.8	35
90	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	0.8	33

#	ARTICLE	IF	CITATIONS
91	Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). <i>Oncologist</i> , 2014, 19, 291-298.	1.9	70
92	Bendamustine plus rituximab in MALT lymphoma. <i>Lancet Haematology</i> , 2014, 1, e88-e89.	2.2	1
93	MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.	1.5	38
94	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014, 24, 33-42.	4.3	80
95	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the international extranodal lymphoma study group. <i>British Journal of Haematology</i> , 2014, 166, 69-76.	1.2	39
96	Intravascular Large B Cell Lymphoma: Widespread but Not Everywhere. <i>Acta Haematologica</i> , 2014, 131, 16-17.	0.7	7
97	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	3.2	117
98	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	3.2	60
99	Risk of CNS dissemination in extranodal lymphomas. <i>Lancet Oncology</i> , 2014, 15, e159-e169.	5.1	37
100	De-escalating therapy in gastric aggressive lymphoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 8993-7.	1.4	10
101	Marginal zone lymphomas and infectious agents. <i>Seminars in Cancer Biology</i> , 2013, 23, 431-440.	4.3	76
102	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	0.6	14
103	Ten Years of International Primary CNS Lymphoma Collaborative Group Studies. <i>Journal of Clinical Oncology</i> , 2013, 31, 3444-3445.	0.8	10
104	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. <i>Hematological Oncology</i> , 2013, 31, 143-150.	0.8	66
105	Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 216-237.	2.0	93
106	Diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 146-171.	2.0	323
107	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
108	Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. <i>British Journal of Haematology</i> , 2013, 160, 47-52.	1.2	79

#	ARTICLE	IF	CITATIONS
109	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
110	The role of <i>Helicobacter pylori</i> eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. <i>Current Opinion in Oncology</i> , 2013, 25, 470-479.	1.1	32
111	A Reappraisal of the Diagnostic and Therapeutic Management of Uncommon Histologies of Primary Ocular Adnexal Lymphoma. <i>Oncologist</i> , 2013, 18, 876-884.	1.9	36
112	Gains of <i>CCND3</i> gene in ocular adnexal MALT lymphomas: an integrated analysis. <i>British Journal of Haematology</i> , 2013, 160, 719-722.	1.2	6
113	Current uses of radiation therapy in patients with primary CNS lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1327-1337.	1.1	19
114	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 2630-2640.	0.6	46
115	Single nucleotide variation in the TP53 untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	0.6	41
116	Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 3055-3055.	0.6	0
117	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 365-365.	0.6	1
118	Long-Term Remission of HIV-Associated Primary CNS Lymphoma Achieved With Highly Active Antiretroviral Therapy Alone. <i>Journal of Clinical Oncology</i> , 2012, 30, e119-e121.	0.8	18
119	Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	0.8	107
120	Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2012, 17, 838-846.	1.9	114
121	Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1609-1618.	2.1	52
122	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	0.6	85
123	<i>Helicobacter pylori</i> eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012, 120, 3858-3860.	0.6	58
124	Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 252-255.	1.2	15
125	<i>Chlamydomoeba psittaci</i> Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexal Lymphoma: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2988-2994.	0.8	167
126	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	0.6	301



#	ARTICLE	IF	CITATIONS
127	Primary CNS lymphoma. Best Practice and Research in Clinical Haematology, 2012, 25, 119-130.	0.7	52
128	Hepatosplenic gamma-delta T-cell lymphoma. Critical Reviews in Oncology/Hematology, 2012, 83, 283-292.	2.0	51
129	Anaplastic large cell lymphoma, ALK-positive. Critical Reviews in Oncology/Hematology, 2012, 83, 293-302.	2.0	98
130	Appraisal of recent knowledge in primary central nervous system lymphoma. Memo - Magazine of European Medical Oncology, 2012, 5, 285-288.	0.3	0
131	Ocular Adnexal Lymphoma of MALT-Type and Its Association with Chlamydomphila psittaci Infection. , 2012, , 139-163.		0
132	Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. British Journal of Clinical Pharmacology, 2012, 73, 240-247.	1.1	28
133	Intraocular Lymphoma. , 2012, , 199-218.		1
134	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2011, 29, 2766-2772.	0.8	190
135	Central nervous system marginal zone B-cell lymphoma associated with Chlamydomphila psittaci infection. Human Pathology, 2011, 42, 738-742.	1.1	18
136	Intralesional Rituximab. Ophthalmology, 2011, 118, 24-28.	2.5	70
137	Whole-brain radiotherapy in primary CNS lymphoma. Lancet Oncology, The, 2011, 12, 118-119.	5.1	37
138	Gastric lymphoma: The histology report. Digestive and Liver Disease, 2011, 43, S310-S318.	0.4	25
139	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	0.6	173
140	How I treat primary CNS lymphoma. Blood, 2011, 118, 510-522.	0.6	162
141	Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica, 2011, 96, 1064-1066.	1.7	42
142	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. British Journal of Haematology, 2011, 153, 499-503.	1.2	12
143	Gains of <i>MYC</i> locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. British Journal of Haematology, 2011, 155, 274-277.	1.2	47
144	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Annals of Hematology, 2011, 90, 401-408.	0.8	28

#	ARTICLE	IF	CITATIONS
145	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41.	0.8	29
146	Consolidation Radiotherapy in Primary Central Nervous System Lymphomas: Impact on Outcome of Different Fields and Doses in Patients in Complete Remission After Upfront Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 169-175.	0.4	56
147	Enteropathy-associated T-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 84-90.	2.0	83
148	Peripheral T-cell lymphoma "Not otherwise specified. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 321-329.	2.0	95
149	Lymphoblastic lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 330-343.	2.0	141
150	Prevalence of <i>Borrelia burgdorferi</i> Infection in a Series of 98 Primary Cutaneous Lymphomas. <i>Oncologist</i> , 2011, 16, 1582-1588.	1.9	61
151	Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination. <i>Oncologist</i> , 2011, 16, 336-341.	1.9	30
152	Activity of Clarithromycin in Mucosa-Associated Lymphoid Tissue-Type Lymphomas. <i>Chest</i> , 2011, 139, 724-725.	0.4	6
153	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	0.6	3
154	Primary Central Nervous System Lymphomas: Salvage Treatment. , 2011, , 337-351.		0
155	Treatment approaches for primary CNS lymphomas. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1263-1276.	0.9	15
156	Genetic and epigenetic changes linked to <i>Chlamydia psittaci</i> -associated ocular adnexal lymphomas. <i>Hematological Oncology</i> , 2010, 28, 1-2.	0.8	15
157	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. <i>International Journal of Cancer</i> , 2010, 127, 2300-2312.	2.3	86
158	Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. <i>British Journal of Haematology</i> , 2010, 150, 226-229.	1.2	72
159	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP <sup>21</sup> . <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
160	Consolidation Radiotherapy for a Rare Case of Extranodal Mucosa-Associated Lymphoid Tissue Non-Hodgkin's Lymphoma Synchronous with Prostate Adenocarcinoma. <i>Tumori</i> , 2010, 96, 498-502.	0.6	5
161	Ocular Adnexal Lymphoma: Diffusion-weighted MR Imaging for Differential Diagnosis and Therapeutic Monitoring. <i>Radiology</i> , 2010, 256, 565-574.	3.6	100
162	Flows and flaws in primary central nervous system lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-2.	12.5	75

#	ARTICLE	IF	CITATIONS
163	Unconventional therapies in ocular adnexal lymphomas. Expert Review of Anticancer Therapy, 2010, 10, 1341-1343.	1.1	2
164	Marginal zone B-cell lymphoma of the conjunctiva. Expert Review of Ophthalmology, 2010, 5, 177-188.	0.3	3
165	Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematological Oncology, 2009, 27, 61-70.	0.8	70
166	Primary intracranial meningeal marginal zone B cell lymphoma of malt type (PMML) with osseous infiltration. Annals of Hematology, 2009, 88, 599-601.	0.8	4
167	Chlorambucil <i>versus</i> observation after anti- <i>Helicobacter</i> therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. British Journal of Haematology, 2009, 144, 367-375.	1.2	60
168	Chlamydial infection: the link with ocular adnexal lymphomas. Nature Reviews Clinical Oncology, 2009, 6, 658-669.	12.5	57
169	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, The, 2009, 374, 1512-1520.	6.3	588
170	Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here?. Blood, 2009, 114, 3499-3499.	0.6	3
171	Primary testicular lymphoma. Critical Reviews in Oncology/Hematology, 2008, 65, 183-189.	2.0	106
172	Angioimmunoblastic T-cell lymphoma. Critical Reviews in Oncology/Hematology, 2008, 68, 264-271.	2.0	64
173	<i>Chlamydia psittaci</i> is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: Results of a single prospective case-control study. International Journal of Cancer, 2008, 123, 1089-1093.	2.3	66
174	Mycosis fungoides. Critical Reviews in Oncology/Hematology, 2008, 65, 172-182.	2.0	75
175	Follicular lymphomas. Critical Reviews in Oncology/Hematology, 2008, 66, 248-261.	2.0	44
176	Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Critical Reviews in Oncology/Hematology, 2008, 67, 172-185.	2.0	75
177	Primary mediastinal large B-cell lymphoma. Critical Reviews in Oncology/Hematology, 2008, 68, 256-263.	2.0	60
178	The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in Western™ patients with intravascular large B-cell lymphoma. British Journal of Haematology, 2008, 143, 253-257.	1.2	96
179	High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leukemia and Lymphoma, 2008, 49, 2042-2047.	0.6	45
180	Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leukemia and Lymphoma, 2008, 49, 43-51.	0.6	116

#	ARTICLE	IF	CITATIONS
181	The impact of histopathologic diagnosis on the proper management of testis neoplasms. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 619-622.	4.3	8
182	Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?. <i>Journal of Clinical Oncology</i> , 2008, 26, 5134-5136.	0.8	61
183	Chlamydia Infection and Lymphomas: Association Beyond Ocular Adnexal Lymphomas Highlighted by Multiple Detection Methods. <i>Clinical Cancer Research</i> , 2008, 14, 5794-5800.	3.2	83
184	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 1364-1371.	1.7	66
185	CNS Hodgkin lymphoma. <i>Blood</i> , 2008, 112, 1658-1661.	0.6	76
186	Variable association between <i>Chlamydia psittaci</i> infection and ocular adnexal lymphomas: methodological biases or true geographical variations?. <i>Anti-Cancer Drugs</i> , 2008, 19, 761-765.	0.7	37
187	A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type. <i>Blood</i> , 2008, 112, 3062-3062.	0.6	2
188	Intravascular large B-cell lymphoma. , 2008, , 147-154.		29
189	Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the Nature of the Antigenic Stimulation. <i>Blood</i> , 2008, 112, 623-623.	0.6	0
190	The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). <i>Blood</i> , 2008, 112, 3608-3608.	0.6	0
191	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 478-478.	0.6	0
192	A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals. <i>Pathobiology</i> , 2007, 74, 264-269.	1.9	3
193	Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. <i>Haematologica</i> , 2007, 92, 486-492.	1.7	164
194	A Woman and Her Canary: A Tale of Chlamydiae and Lymphomas. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1418-1419.	3.0	30
195	Primary CNS Lymphomas Prognosis. <i>Journal of Clinical Oncology</i> , 2007, 25, 4322-4324.	0.8	8
196	Primary central nervous system lymphoma – Biological aspects and controversies in management. <i>European Journal of Cancer</i> , 2007, 43, 1141-1152.	1.3	60
197	Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate. <i>Cancer Letters</i> , 2007, 258, 165-170.	3.2	32
198	Therapeutic management of ocular adnexal MALT lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1073-1083.	0.9	7

#	ARTICLE	IF	CITATIONS
199	Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2007, 25, 3168-3173.	0.8	449
200	Primary diffuse large B-cell lymphoma of the stomach. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 65-71.	2.0	82
201	Chronic lymphocytic leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 234-246.	2.0	84
202	Marginal-zone lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 245-256.	2.0	59
203	Primary central nervous system lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 257-268.	2.0	34
204	Infectious Agents in Mucosa-Associated Lymphoid Tissue-“Type Lymphomas: Pathogenic Role and Therapeutic Perspectives. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 289-300.	1.4	39
205	Association between <i>Helicobacter pylori</i> infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. <i>Hematological Oncology</i> , 2006, 24, 33-37.	0.8	48
206	Intravascular lymphoma: a neoplasm of “homeless” lymphocytes?. <i>Hematological Oncology</i> , 2006, 24, 105-112.	0.8	132
207	Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1375-1382.	3.0	201
208	Re: Evidence for an Association Between <i>Chlamydia psittaci</i> and Ocular Adnexal Lymphomas. <i>Journal of the National Cancer Institute</i> , 2006, 98, 365-366.	3.0	47
209	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.5	83
210	Establishing a prognostic score for primary CNS lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 303-304.	0.4	9
211	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-“ <i>Helicobacter Pylori</i> Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	0.8	265
212	Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 2233-2239.	0.8	188
213	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5034-5043.	0.8	729
214	Regression of Ocular Adnexal Lymphoma After <i>Chlamydia Psittaci</i> “Eradicating Antibiotic Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 5067-5073.	0.8	211
215	Target delineation in post-operative radiotherapy of brain gliomas: Interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. <i>Radiotherapy and Oncology</i> , 2005, 75, 217-223.	0.3	54
216	Prognostic Factors in Primary Central Nervous System Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 629-649.	0.9	27

#	ARTICLE	IF	CITATIONS
217	Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. <i>Haematologica</i> , 2005, 90, 1578-9.	1.7	67
218	Evidence for an Association Between <i>Chlamydia psittaci</i> and Ocular Adnexal Lymphomas. <i>Journal of the National Cancer Institute</i> , 2004, 96, 586-594.	3.0	533
219	Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1165-1167.	0.8	18
220	Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. <i>British Journal of Haematology</i> , 2004, 126, 657-664.	1.2	73
221	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the "cutaneous variant"™1. <i>British Journal of Haematology</i> , 2004, 127, 173-183.	1.2	535
222	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004, 17, 1513-1520.	2.9	20
223	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , 2004, 40, 1682-1688.	1.3	118
224	No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1819-20.	1.1	2
225	Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: Identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. <i>International Journal of Cancer</i> , 2003, 106, 288-291.	2.3	28
226	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. <i>Journal of Pathology</i> , 2003, 200, 596-601.	2.1	8
227	International Collaborative Group Against Primary CNS Lymphomas. <i>Journal of Clinical Oncology</i> , 2003, 21, 1649-1650.	0.8	19
228	Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. <i>Journal of Clinical Oncology</i> , 2003, 21, 266-272.	0.8	688
229	Current therapeutic approaches to primary CNS lymphoma. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 673-683.	1.4	2
230	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003, 101, 2489-2495.	0.6	494
231	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	0.6	391
232	Questions and answers in the management of primary central nervous system and ocular lymphomas. <i>Haematologica</i> , 2003, 88, 1063-8.	1.7	3
233	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002, 118, 218-228.	1.2	19
234	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2002, 118, 817-820.	1.2	87

#	ARTICLE	IF	CITATIONS
235	Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 483-488.	0.4	103
236	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002, 87, 1258-64.	1.7	141
237	Therapeutic management of primary CNS lymphoma in immunocompetent patients. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 382-394.	1.1	4
238	Irradiation Fields and Doses in Glioblastoma Multiforme: Are Current Standards Adequate?. <i>Tumori</i> , 2001, 87, 85-90.	0.6	2
239	Prognostic Significance of the Histopathologic Recognition of Low-and High-Grade Components in Stage I-II B-Cell Gastric Lymphomas. <i>American Journal of Surgical Pathology</i> , 2001, 25, 95-102.	2.1	64
240	Central nervous system lymphoma. , 2001, , 200-214.		1
241	Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients. <i>Oncology</i> , 2001, 60, 134-140.	0.9	82
242	Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 651-658.	0.4	71
243	Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 419-425.	0.4	82
244	Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2001, 94, 599-604.	2.3	21
245	Consolidation Radiotherapy to Bulky or Semibulky Lesions in the Management of Stage III-IV Diffuse Large B Cell Lymphomas. <i>Oncology</i> , 2000, 58, 219-226.	0.9	56
246	A Retrospective Analysis of Postradiation Chemotherapy in 133 Patients with Glioblastoma Multiforme. <i>Cancer Investigation</i> , 2000, 18, 510-515.	0.6	12
247	Therapeutic Management of Stage I-II High-Grade Primary Gastric Lymphomas. <i>Oncology</i> , 1999, 56, 274-282.	0.9	30
248	Diffuse Large-Cell Lymphoma of the Testis. <i>Journal of Clinical Oncology</i> , 1999, 17, 2854-2854.	0.8	82
249	Therapeutic Management with Adriamycin-Containing Chemotherapy and Radiotherapy of Monostotic and Polyostotic Primary Non-Hodgkin's Lymphoma of Bone in Adults. <i>Cancer Investigation</i> , 1998, 16, 554-561.	0.6	25
250	Role of Dose Intensity in Conservative Treatment of Anal Canal Carcinoma. <i>Oncology</i> , 1998, 55, 525-532.	0.9	16
251	Low Sensitivity of Computed Tomography in the Staging of Gastric Lymphomas of Mucosa-Associated Lymphoid Tissue. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 614-616.	0.6	4
252	Primary brain lymphomas in patients with a prior or concomitant malignancy. <i>Journal of Neuro-Oncology</i> , 1997, 32, 135-142.	1.4	22

#	ARTICLE	IF	CITATIONS
253	Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. , 1996, 77, 827-833.		79
254	Primary central nervous system lymphoma in immunocompetent patients. Cancer Treatment Reviews, 1995, 21, 415-446.	3.4	30
255	Production and Characterization of a Monoclonal Antibody Against the Ribosome Inactivating Protein Alpha Sarcin. Hybridoma, 1992, 11, 437-446.	0.9	4
256	Central nervous system lymphomas. , 0, , 208-225.		0
257	Risk stratification and management algorithms for patients with diffuse large B-cell lymphoma and CNS involvement. Annals of Lymphoma, 0, 3, 7-7.	4.5	8
258	Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial. Blood Advances, 0, , .	2.5	0